Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic immune thrombocytopenia
Biotech
ASH: Novartis details ianalumab's phase 3 rare blood disease win
If the combo therapy's boosted platelet counts persist even longer, it could "change the treatment paradigm" for primary immune thrombocytopenia.
Darren Incorvaia
Dec 9, 2025 7:30am
Mountainfield, China's Keymed launch biotech with $180M series A
Jan 10, 2025 8:43am
Sanofi BTK inhibitor for blood disease raises platelet levels
Nov 5, 2024 1:42pm
Takeda's anti-CD38 antibody boosts platelet count in phase 2
Jun 24, 2024 8:58am
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Apr 23, 2024 2:23am
Hutchmed eyes China approval for autoimmune drug after ph. 3 win
Aug 21, 2023 8:45am
